CytomX Therapeutics carries a rejected, implausible analyst target and a sub-floor quality score alongside severe cash burn, but its 200-day moving average is still rising and the setup reads as a pullback rather than a confirmed breakdown, keeping the position an exit candidate pending a reliable valuation anchor.
Thesis pillars
- Implausible Analyst Target Flag→Stable
- Momentum Pullback Not Breakdown→Stable
- Quality Floor Exit Signal→Stable
- +2 more pillars — see the Why tab for full reasoning
CytomX Therapeutics, Inc. (CTMX) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $3.81: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 3.7/10. Specifically: High short interest: 16%; Below-average business quality; Rich valuation.
CytomX Therapeutics is a clinical-stage biopharmaceutical company developing conditionally activated 'PROBODY' biologics, led by Varseta-M, an antibody-drug conjugate targeting EpCAM in late-line metastatic colorectal cancer, and CX-801, a masked interferon alpha-2b tested with... Read more
Sell if holding. Engine safety override at $3.81: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 3.7/10. Specifically: High short interest: 16%; Below-average business quality; Rich valuation. Chart setup: No clear chart pattern; technical signals are mixed. Score 3.7/10, high confidence.
Passes 6/8 gates (positive momentum, clean insider activity, news events none recent, earnings proximity 32d clear, semi cycle peak clear, materials cycle peak clear). Suitability: speculative.
About CytomX Therapeutics, Inc.
About CytomX Therapeutics, Inc.
CytomX Therapeutics' most advanced clinical program, Varseta-M, is a conditionally activated antibody-drug conjugate targeting EpCAM that reported a 32% confirmed response rate at its 10 mg/kg dose in a January 2026 Phase 1 expansion data cutoff spanning 93 late-line metastatic colorectal cancer patients. The clinical-stage biopharmaceutical company had an accumulated deficit of $711.9 million as of December 31, 2025, funded in part by a $93.4 million public offering completed in May 2025.
CytomX built its pipeline on the PROBODY platform, which masks biologic therapeutics so they activate only after tumor-associated proteases remove the mask, and applies that masking strategy across antibody-drug conjugates, T-cell engagers, and cytokines. Varseta-M pairs a licensed AbbVie/ImmunoGen topoisomerase-1 payload with an EpCAM-targeting antibody and is advancing toward a potential registrational study in late-line colorectal cancer, while the company's second clinical asset, CX-801, a masked interferon alpha-2b, is being tested in combination with Merck's KEYTRUDA in advanced melanoma. Beyond its two lead programs, CytomX maintains preclinical PROBODY collaborations with Amgen, Bristol Myers Squibb, Astellas, Regeneron, and Moderna, extending the platform's reach without requiring CytomX to fund every program alone. In January 2025 the company cut headcount by approximately 40% to preserve capital and focus resources on Varseta-M and CX-801.
Show full overview
With no approved products or product revenue, CytomX's near-term value is concentrated almost entirely in Varseta-M's late-line CRC readout, since the company's May 2025 financing was sized to fund operations only into the second quarter of 2027 — a runway that assumes no material setback in either clinical program. A single Grade 5 treatment-related kidney injury reported in a patient with a pre-existing solitary kidney, disclosed August 13, 2025 and reviewed by the study's safety committee without halting enrollment, illustrates the kind of adverse-event signal that could alter the registrational timeline this concentrated pipeline depends on.
See also: Healthcare · Biotechnology
From CytomX Therapeutics, Inc.'s most recent 10-K filing, extracted July 6, 2026.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHpipelineVarseta-M10-K Item 1: 'Our most advanced clinical-stage program is Varseta-M, an investigational, conditionally activated antibody-drug conjugate ("ADC") targeting epithelial cell adhesion molecule ("EpCAM").'
Material Events(8-K, last 90d)
- 2026-06-22Item 5.02LOWStockholders approved amendments increasing shares authorized under the 2015 Equity Incentive Plan by 6,500,000 and the ESPP by 1,000,000 at the June 17, 2026 annual meeting; routine equity-plan expansion, not an executive departure.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
5 floor-breakers
Priced at a premium — multiples above sector norms. Needs delivery on growth + margins to justify.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Unprofitable operations — net margin -166.4%. Quality floor flags this regardless of sector context.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $3.81: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 3.7/10. Specifically: High short interest: 16%; Below-average business quality; Rich valuation. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $3.54. Score 3.7/10, high confidence.
Take-profit target: $3.82 (+0.3% upside). Prior stop was $3.54. Stop-loss: $3.54.
Concentration risk — Pipeline: Varseta-M; DATA_ISSUE: analyst_target_implausible (raw $12.50 vs price $3.81 — ratio 3.3×). Rejected, falling back to technical TP.; Quality below floor (3.2 < 4.0).
CytomX Therapeutics, Inc. trades at a P/E of N/A (forward -7.9). TrendMatrix value score: 0.0/10. Verdict: Sell.
14 analysts cover CTMX with a consensus score of 4.4/5. Average price target: $13.
What does CytomX Therapeutics, Inc. do?CytomX Therapeutics is a clinical-stage biopharmaceutical company developing conditionally activated 'PROBODY'...
CytomX Therapeutics is a clinical-stage biopharmaceutical company developing conditionally activated 'PROBODY' biologics, led by Varseta-M, an antibody-drug conjugate targeting EpCAM in late-line metastatic colorectal cancer, and CX-801, a masked interferon alpha-2b tested with Merck's KEYTRUDA in melanoma. The company has generated no product revenue, held an accumulated deficit of $711.9 million as of December 31, 2025, and raised $93.4 million in a May 2025 public offering to fund operations into the second quarter of 2027.